Abstract

GONZALEZ VATTEONE, Cecilia et al. Seroprevalence of Toxoplasma Gondii infection in patients with Systemic Lupus Erythematosus. Rev. parag. reumatol. [online]. 2022, vol.8, n.2, pp.77-82. ISSN 2413-4341.  https://doi.org/10.18004/rpr/2022.08.02.77.

Abstract: Objectives: The purpose of the study was to determine the seroprevalence of Toxoplasma gondii infection and to describe the clinical characteristics of lupus activity in patients with Systemic Lupus Erythematosus whose samples were stored in an autoimmune disease biobank and were collected between 2013 and 2015. Methodology: A retrospective, cross-sectional study was conducted in patients with SLE. Demographic and clinical data were collected from patient charts. Qualitative and quantitative measurement of IgG anti-Toxoplasma gondii antibodies was performed. Results: The study included 106 patients with SLE, 88.68% female, with a median age of 31.00 years (RI: 24 - 59). The seroprevalence of toxoplasmosis was 72.64%. The most frequently used immunosuppressive treatment was Hydroxychloroquine and the majority (76.19%) used a combination of drugs. Conclusion: The seroprevalence of toxoplasmosis was determined in the study populati on, and the result was close to the upper limit of the range reported in studies performed in rheumatologic patients. This shows the importance of carrying out further research in similar populations and of including the determination of IgG anti-T. gondii antibodies in the routine studies performed in these patients.

Keywords : Systemic Lupus Erythematosus; Toxoplasmosis; immunosuppression therapy.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )